Survival Outcome and Prognostic Factors After Pulmonary Metastasectomy in Sarcoma Patients
Umberto Cariboni(IRCCS Humanitas Research Hospital), Marco Alloisio(IRCCS Humanitas Research Hospital), Vittorio Quagliuolo(Humanitas University), Rita De Sanctis(Humanitas University), Andrea Marrari(IRCCS Humanitas Research Hospital), Pierina Navarria(IRCCS Humanitas Research Hospital), Emanuele Voulaz(Humanitas University), Pierluigi Novellis(IRCCS Ospedale San Raffaele), Emanuela Morenghi(Humanitas University), Piergiuseppe Colombo(Humanitas University), Edoardo Bottoni(Thoracic Surgery Foundation), Marta Giaretta(Thoracic Surgery Foundation), Alberto Testori(IRCCS Humanitas Research Hospital), Marta Scorsetti(Humanitas University), Valentina Errico(IRCCS Humanitas Research Hospital), Armando Santoro(IRCCS Humanitas Research Hospital), A.M. Ascolese(IRCCS Humanitas Research Hospital), Alessandro Crepaldi(Thoracic Surgery Foundation)
Cited by 31
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646